Literature DB >> 28458054

A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2.

Wentian Guo1, Sue-Jane Wang2, Shengjie Yang3, Henry Lynn1, Yuan Ji4.   

Abstract

There has been an increasing interest in using interval-based Bayesian designs for dose finding, one of which is the modified toxicity probability interval (mTPI) method. We show that the decision rules in mTPI correspond to an optimal rule under a formal Bayesian decision theoretic framework. However, the probability models in mTPI are overly sharpened by the Ockham's razor, which, while in general helps with parsimonious statistical inference, leads to undesirable decisions from safety perspective. We propose a new framework that blunts the Ockham's razor, and demonstrate the superior performance of the new method, called mTPI-2. An online web tool is provided for users who can generate the design, conduct clinical trials, and examine operating characteristics of the designs.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bayes rule; Crowd sourcing; Decision theory; Phase I clinical trial

Mesh:

Year:  2017        PMID: 28458054     DOI: 10.1016/j.cct.2017.04.006

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  13 in total

1.  Coherence principles in interval-based dose finding.

Authors:  Nolan A Wages; Alexia Iasonos; John O'Quigley; Mark R Conaway
Journal:  Pharm Stat       Date:  2019-11-06       Impact factor: 1.894

Review 2.  Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority.

Authors:  Ying Yuan; J Jack Lee; Susan G Hilsenbeck
Journal:  JCO Precis Oncol       Date:  2019-10-24

3.  AAA: triple adaptive Bayesian designs for the identification of optimal dose combinations in dual-agent dose finding trials.

Authors:  Jiaying Lyu; Yuan Ji; Naiqing Zhao; Daniel V T Catenacci
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2018-06-13       Impact factor: 1.864

4.  Bayesian Sample Size Planning Tool for Phase I Dose-Finding Trials.

Authors:  Xiaolei Lin; Jiaying Lyu; Shijie Yuan; Dehua Bi; Sue-Jane Wang; Yuan Ji
Journal:  JCO Precis Oncol       Date:  2022-08

Review 5.  An overview of the BOIN design and its current extensions for novel early-phase oncology trials.

Authors:  Revathi Ananthakrishnan; Ruitao Lin; Chunsheng He; Yanping Chen; Daniel Li; Michael LaValley
Journal:  Contemp Clin Trials Commun       Date:  2022-06-13

Review 6.  Novel clinical trial design and analytic methods to tackle challenges in therapeutic development in rare diseases.

Authors:  Yimei Li; Rima Izem
Journal:  Ann Transl Med       Date:  2022-09

7.  Continual reassessment method with regularization in phase I clinical trials.

Authors:  Xiang Li; Anastasia Ivanova; Hong Tian; Pilar Lim; Kevin Liu
Journal:  J Biopharm Stat       Date:  2020-09-14       Impact factor: 1.051

8.  Operating characteristics are needed to properly evaluate the scientific validity of phase I protocols.

Authors:  Nolan A Wages; Bethany Jablonski Horton; Mark R Conaway; Gina R Petroni
Journal:  Contemp Clin Trials       Date:  2021-07-25       Impact factor: 2.261

9.  Logistic retainment interval dose exploration design for Phase I clinical trials of cytotoxic agents.

Authors:  Thomas A Murray
Journal:  Pharm Stat       Date:  2021-03-18       Impact factor: 1.234

10.  Overall success rate of a safe and efficacious drug: Results using six phase 1 designs, each followed by standard phase 2 and 3 designs.

Authors:  Amy S Ruppert; Abigail B Shoben
Journal:  Contemp Clin Trials Commun       Date:  2018-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.